ReShape LifesciencesRSLS
RSLS
About: Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
Employees: 31
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,089% more capital invested
Capital invested by funds: $7.17K [Q3] → $85.2K (+$78.1K) [Q4]
2.44% more ownership
Funds ownership: 0.25% [Q3] → 2.69% (+2.44%) [Q4]
10% less funds holding
Funds holding: 10 [Q3] → 9 (-1) [Q4]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for RSLS.
Financial journalist opinion
Based on 3 articles about RSLS published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia
Neutral
GlobeNewsWire
2 weeks ago
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX
Liaison Medical is Among the Largest Surgical Device Distributors in Canada Liaison Medical is Among the Largest Surgical Device Distributors in Canada
Neutral
GlobeNewsWire
3 weeks ago
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
IRVINE, Calif., Feb. 15, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 2,575,107 units at a public offering price of $2.33 per unit. Each unit consists of one common share (or pre-funded warrant to purchase one common share in-lieu thereof) and one warrant to purchase one common share.
Neutral
GlobeNewsWire
1 month ago
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia
Neutral
GlobeNewsWire
1 month ago
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
IRVINE, Calif. and CAMBRIDGE, Mass.
Neutral
Seeking Alpha
3 months ago
ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO Krishna Gupta - Director, Vyome Therapeutics Conference Call Participants Jason McCarthy - Maxim Group Operator Good afternoon, and thank you for joining the ReShape Lifesciences Third Quarter 2024 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications.
Neutral
GlobeNewsWire
3 months ago
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024
Neutral
GlobeNewsWire
4 months ago
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health Canada has updated the Medical Device License granting approval for the company's next generation, enhanced Lap-Band® 2.0 FLEX and Tubing Kit.
Neutral
GlobeNewsWire
4 months ago
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology
Approximately $241,000 Grant Will Be Utilized to Conduct Minimally Invasive Laparoscopic Surgical Electrode Implantation Techniques and Long Duration Safety and Blood Glucose Modulation Experiments for the CARSS Project Approximately $241,000 Grant Will Be Utilized to Conduct Minimally Invasive Laparoscopic Surgical Electrode Implantation Techniques and Long Duration Safety and Blood Glucose Modulation Experiments for the CARSS Project
Neutral
GlobeNewsWire
5 months ago
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
IRVINE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-58 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on September 23, 2024.
Charts implemented using Lightweight Charts™